TY - JOUR
T1 - Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
AU - Adjei, Alex A.
AU - Erlichman, Charles
AU - Sloan, Jeff A.
AU - Reid, Joel M.
AU - Pitot, Henry C.
AU - Goldberg, Richard M.
AU - Peethambaram, Prema
AU - Atherton, Pamela
AU - Hanson, Lorelei J.
AU - Alberts, Steven R.
AU - Jett, James
PY - 2000/4
Y1 - 2000/4
N2 - Purpose: Multitargeted antifolate (MTA) is an investigational agent that, like gemcitabine, exhibits broad activity in solid tumors. A phase 1 trial of MTA and gemcitabine was undertaken, based on the demonstration of preclinical cytotoxic synergy. Patients and Methods: Thirty-five patients (group I) received 164 courses (median, four; range, one to 14 courses) of treatment of gemcitabine at doses of 1,000 and 1,250 mg/m2 on days 1 and 8 and MTA at doses of 200, 300, 400, 500, and 600 mg/m2, given 90 minutes after gemcitabine on day 1. Courses were repeated every 3 weeks. Because the day 8 dose of gemcitabine was reduced or omitted in 57% of courses due to neutropenia, 21 patients (group II) were treated on an alternate schedule, with MTA administered on day 8 rather than day 1. This group received 85 treatment courses (median, four; range, one to 10 courses). Results: The most common and dose-limiting toxicity was neutropenia. Other toxicities included nausea, fatigue, rash, and elevated hepatic transaminases. The maximum- tolerated dose was gemcitabine/MTA 1,000/500 mg/m2 for group I and 1,250/500 mg/m2 for group II. Thirteen objective responses were documented (colorectal cancer, n = 3; non-small-cell lung cancer, n = 3; cholangiocarcinoma, n = 2; ovarian carcinoma, n = 2; mesothelioma, n = 1; breast cancer, n = 1; and adenocarcinoma of unknown primary site, n = 1). Gemcitabine had no effect on the disposition of MTA. Conclusion: The gemcitabine/MTA combination is broadly active and warrants further evaluation. The sequence of gemcitabine administered on days 1 and 8 with MTA administered on day 8 is better tolerated arid is recommended for further study at doses of gemcitabine/MTA 1,250/500 mg/m2. (C) 2000 by American Society of Clinical Oncology.
AB - Purpose: Multitargeted antifolate (MTA) is an investigational agent that, like gemcitabine, exhibits broad activity in solid tumors. A phase 1 trial of MTA and gemcitabine was undertaken, based on the demonstration of preclinical cytotoxic synergy. Patients and Methods: Thirty-five patients (group I) received 164 courses (median, four; range, one to 14 courses) of treatment of gemcitabine at doses of 1,000 and 1,250 mg/m2 on days 1 and 8 and MTA at doses of 200, 300, 400, 500, and 600 mg/m2, given 90 minutes after gemcitabine on day 1. Courses were repeated every 3 weeks. Because the day 8 dose of gemcitabine was reduced or omitted in 57% of courses due to neutropenia, 21 patients (group II) were treated on an alternate schedule, with MTA administered on day 8 rather than day 1. This group received 85 treatment courses (median, four; range, one to 10 courses). Results: The most common and dose-limiting toxicity was neutropenia. Other toxicities included nausea, fatigue, rash, and elevated hepatic transaminases. The maximum- tolerated dose was gemcitabine/MTA 1,000/500 mg/m2 for group I and 1,250/500 mg/m2 for group II. Thirteen objective responses were documented (colorectal cancer, n = 3; non-small-cell lung cancer, n = 3; cholangiocarcinoma, n = 2; ovarian carcinoma, n = 2; mesothelioma, n = 1; breast cancer, n = 1; and adenocarcinoma of unknown primary site, n = 1). Gemcitabine had no effect on the disposition of MTA. Conclusion: The gemcitabine/MTA combination is broadly active and warrants further evaluation. The sequence of gemcitabine administered on days 1 and 8 with MTA administered on day 8 is better tolerated arid is recommended for further study at doses of gemcitabine/MTA 1,250/500 mg/m2. (C) 2000 by American Society of Clinical Oncology.
UR - http://www.scopus.com/inward/record.url?scp=0033993714&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033993714&partnerID=8YFLogxK
U2 - 10.1200/JCO.2000.18.8.1748
DO - 10.1200/JCO.2000.18.8.1748
M3 - Article
C2 - 10764436
AN - SCOPUS:0033993714
SN - 0732-183X
VL - 18
SP - 1748
EP - 1757
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 8
ER -